Neilmed Pharmaceuticals Inc – FDA 483, Jul 22, 2026

Neilmed Pharmaceuticals Inc. received a Form 483 citing multiple deficiencies across its quality control, training, equipment cleaning, calibration, material specifications, and warehousing operations. Issues included inadequate laboratory record control, unreviewed contract testing reports, insufficient employee competence verification, rusty equipment use, and unsecured labeling storage, indicating a systemic lack of adherence to established procedures and GMP requirements.